Text Size: a  |   a 

Update on Pipeline Drug: Zinbryta

May 10, 2016

In the late summer we heard about Zinbryta being evaluated by the FDA for MS Treatment, and now we can give a proper update. The once-monthly injection for multiple sclerosis from Biogen and AbbVie has been recommended for approval by European regulators, paving the way for its launch in the coming months.

The European Medicines Agency said on Friday its experts had endorsed Zinbryta, for the treatment of relapsing forms of multiple sclerosis (MS). This adds another option to a stable of modern MS therapies.

The positive opinion will now be referred to the European Commission, which normally grants marketing authorizations for medicines recommended by the agency within a couple of months. Aside from America which was mentioned before, it is also being reviewed in Australia, Canada and Switzerland.